Actionable news
All posts from Actionable news
Actionable news in ALXN: Alexion Pharmaceuticals, Inc.,

Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now

After racing to all-time highs in late July, the Nasdaq Biotechnology Index (NBI) and the NYSE Arca Biotechnology Index (BTK) then proceeded to decline 18.0% and 18.2% respectively. What really put the hammer down at the end of the quarter was the Turing Pharmaceutical pricing scandal, and then comments from presidential candidate Hillary Clinton on drug pricing and needed reforms. It was the exact kind of populist political rhetoric that can melt a sector.

A new report from Cowen notes that while the sell-off was very large and painful, and the inevitable “bear market” chatter on the sector heated up, the biotech indexes are tracking right about flat for the year, in line with the other major indexes. The firm says the way to play it is with large cap sector leaders that can beat earnings estimates. Cowen also thinks third-quarter earnings beats could highlight the risk of not owning biotech now.

We scanned the Cowen coverage universe for four top stocks that they think can beat earnings estimates for the third quarter. All are rated Outperform.


After posting outstanding second-quarter earnings, the biotech giant remains a top stock for investors to buy. Amgen Inc. (NASDAQ: AMGN) focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Many on Wall Street point to Amgen’s tremendous pipeline and outstanding forward earnings and revenue capabilities. Its double-digit earnings and revenue growth rate is expected to continue for the foreseeable future because of the company’s very deep clinical pipeline, which includes potential blockbusters Repatha for high cholesterol and Kyprolis for relapsed multiple myeloma. Amgen also has one of the sector’s deepest biosimilar pipelines, which is expected to generate upward of $3 billion in annual sales in the...